AbbVie Inc.

ABBV-N

NYSE:ABBV

94.05
1.30 (1.36%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
WAIT
WAIT
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
BUY
BUY
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
BUY
BUY
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
COMMENT
COMMENT
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
TOP PICK
TOP PICK
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
DON'T BUY
DON'T BUY
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
DON'T BUY
DON'T BUY
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
COMMENT
COMMENT
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

COMMENT
COMMENT
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

HOLD
HOLD
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
BUY
BUY
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
BUY
BUY
May 3, 2019

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

Show full opinionHide full opinion

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

DON'T BUY
DON'T BUY
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
PAST TOP PICK
PAST TOP PICK
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
HOLD
HOLD
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Showing 1 to 15 of 54 entries